Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

COVID-19 in JMD

Page Path
HOME > Browse Articles > COVID-19 in JMD
16 COVID-19 in JMD
Filter
Filter
Article category
Keywords
Authors
Funded articles
Letter to the editor
Myorhythmia and Other Movement Disorders in Two Patients With Coronavirus Disease 2019 Encephalopathy
Rebecca Hui Min Hoe, Fan Yang, Siew Kit Shuit, Glenn Khai Wern Yong, Ser Hon Puah, Jennifer Sye Jin Ting, Mucheli Sharavan Sadasiv, Thirugnanam Umapathi
J Mov Disord. 2023;16(2):217-220.   Published online April 26, 2023
DOI: https://doi.org/10.14802/jmd.22215
  • 2,039 View
  • 34 Download
PDFSupplementary Material
Viewpoints
Challenges in Parkinson’s Disease Care—In Light of the COVID-19 Pandemic
Kyung Ah Woo, Han-Joon Kim, Beomseok Jeon
J Mov Disord. 2023;16(1):52-54.   Published online November 10, 2022
DOI: https://doi.org/10.14802/jmd.22085
  • 2,359 View
  • 83 Download
  • 1 Web of Science
  • 1 Crossref
PDF

Citations

Citations to this article as recorded by  
  • Efficacy of telerehabilitation with digital and robotic tools for the continuity of care of people with chronic neurological disorders: The TELENEURO@REHAB protocol for a randomized controlled trial
    Federica Rossetto, Fabiola Giovanna Mestanza Mattos, Elisa Gervasoni, Marco Germanotta, Arianna Pavan, Davide Cattaneo, Irene Aprile, Francesca Baglio
    DIGITAL HEALTH.2024;[Epub]     CrossRef
Mask on, Mask off: Subclinical Parkinson’s Disease Unveiled by COVID-19
Milan Beckers, Bastiaan R Bloem, Rick C Helmich
J Mov Disord. 2023;16(1):55-58.   Published online November 10, 2022
DOI: https://doi.org/10.14802/jmd.22067
  • 3,060 View
  • 99 Download
  • 2 Web of Science
  • 2 Crossref
PDF

Citations

Citations to this article as recorded by  
  • The Last Straw: How Stress Can Unmask Parkinson’s Disease
    Anouk van der Heide, Claudia Trenkwalder, Bastiaan R. Bloem, Rick C. Helmich
    Journal of Parkinson's Disease.2024; 14(4): 889.     CrossRef
  • SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now
    Iro Boura, Mubasher A. Qamar, Francesco Daddoveri, Valentina Leta, Karolina Poplawska-Domaszewicz, Cristian Falup-Pecurariu, K. Ray Chaudhuri
    Biomedicines.2023; 11(9): 2524.     CrossRef
Letters to the editor
Catatonia in Hospitalized Patients With COVID-19: An Important Clinical Finding That Should Not be Missed
Tien Lee Ong, Sapiah Sapuan
J Mov Disord. 2022;15(3):277-280.   Published online May 10, 2022
DOI: https://doi.org/10.14802/jmd.21172
  • 3,665 View
  • 180 Download
  • 1 Web of Science
PDFSupplementary Material
COVID-19 Associated Acute Necrotizing Encephalopathy Presenting as Parkinsonism and Myorhythmia
Tien Lee Ong, Khariah Mat Nor, Yusniza Yusoff, Sapiah Sapuan
J Mov Disord. 2022;15(1):89-92.   Published online November 17, 2021
DOI: https://doi.org/10.14802/jmd.21063
  • 6,196 View
  • 161 Download
  • 14 Web of Science
  • 12 Crossref
PDFSupplementary Material

Citations

Citations to this article as recorded by  
  • Defining the Clinicoradiologic Syndrome of SARS-CoV-2 Acute Necrotizing Encephalopathy
    Vanessa W. Lee, Kai Qian Kam, Ahmad R. Mohamed, Husna Musa, Poorani Anandakrishnan, Qingtang Shen, Alexander F. Palazzo, Russell C. Dale, Ming Lim, Terrence Thomas
    Neurology Neuroimmunology & Neuroinflammation.2024;[Epub]     CrossRef
  • Post-COVID parkinsonism: A scoping review
    Paola Polverino, Antoniangela Cocco, Alberto Albanese
    Parkinsonism & Related Disorders.2024; 123: 106066.     CrossRef
  • Steroid administration for post‐COVID‐19 Parkinsonism: A case report
    Witoon Mitarnun, Metha Apiwattanakul, Thanatchanan Thodthasri, Praewa Tantisungvarakoon, Wilasinee Pangwong
    Neurology and Clinical Neuroscience.2023; 11(1): 49.     CrossRef
  • Movement Disorders andSARS‐CoV‐2
    Wilson K.W. Fung, Alfonso Fasano, Conor Fearon
    Movement Disorders Clinical Practice.2023;[Epub]     CrossRef
  • Myorhythmia and Other Movement Disorders in Two Patients With Coronavirus Disease 2019 Encephalopathy
    Rebecca Hui Min Hoe, Fan Yang, Siew Kit Shuit, Glenn Khai Wern Yong, Ser Hon Puah, Jennifer Sye Jin Ting, Mucheli Sharavan Sadasiv, Thirugnanam Umapathi
    Journal of Movement Disorders.2023; 16(2): 217.     CrossRef
  • Limb myorhythmia treated with chemodenervation: a case report
    Nil Saez-Calveras, Meredith Bryarly, Meagen Salinas
    Therapeutic Advances in Neurological Disorders.2023; 16: 175628642211503.     CrossRef
  • Acute Necrotizing Encephalopathy in Adult Patients With COVID-19: A Systematic Review of Case Reports and Case Series
    Shaghayegh Karami, Fattaneh Khalaj, Houman Sotoudeh, Zohreh Tajabadi, Ramin Shahidi, Mohammad Amin Habibi, Mahsa Shirforoush Sattari, Amir Azimi, Seyed Ali Forouzannia, Romina Rafiei, Hamid Reihani, Reza Nemati, Soraya Teimori, Amirmohammad Khalaji, Vida
    Journal of Clinical Neurology.2023; 19(6): 597.     CrossRef
  • Parkinson’s Disease in Light of the COVID-19 Pandemic
    Anna Drelich-Zbroja, Mateusz Cheda, Maryla Kuczyńska, Izabela Dąbrowska, Ewa Kopyto, Izabela Halczuk
    Brain Sciences.2022; 12(2): 143.     CrossRef
  • Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review
    Jeremy M. Morowitz, Kaylyn B. Pogson, Daniel A. Roque, Frank C. Church
    Brain Sciences.2022; 12(5): 536.     CrossRef
  • Coronavirus Disease 2019 and Related Parkinsonism: The Clinical Evidence Thus Far
    Iro Boura, Kallol Ray Chaudhuri
    Movement Disorders Clinical Practice.2022; 9(5): 584.     CrossRef
  • COVID-19 and Parkinsonism: A Critical Appraisal
    Francesco Cavallieri, Valentina Fioravanti, Francesco Bove, Eleonora Del Prete, Sara Meoni, Sara Grisanti, Marialuisa Zedde, Rosario Pascarella, Elena Moro, Franco Valzania
    Biomolecules.2022; 12(7): 970.     CrossRef
  • Viruses, parkinsonism and Parkinson’s disease: the past, present and future
    Valentina Leta, Daniele Urso, Lucia Batzu, Yue Hui Lau, Donna Mathew, Iro Boura, Vanessa Raeder, Cristian Falup-Pecurariu, Daniel van Wamelen, K. Ray Chaudhuri
    Journal of Neural Transmission.2022; 129(9): 1119.     CrossRef
Review Articles
Parkinson’s Disease and the COVID-19 Pandemic: A Review Article on the Association between SARS-CoV-2 and α-Synucleinopathy
Smriti Sinha, Swati Mittal, Rupali Roy
J Mov Disord. 2021;14(3):184-192.   Published online July 29, 2021
DOI: https://doi.org/10.14802/jmd.21046
  • 7,044 View
  • 218 Download
  • 13 Web of Science
  • 14 Crossref
AbstractAbstract PDF
There is an extensive debate on the neurological consequences of 2019 novel coronavirus disease (COVID-19) and its impact on Parkinson’s disease (PD) patients, which seems to puzzle neurologists. Links between viral infections and PD have long been suspected and studied, but the exact relationship remains elusive. Since severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) enters the brain through multiple routes and has a direct impact on the brain, cumulative damage occurs due to the activation of proinflammatory cytokines and chemokines. SARS-CoV-2 seems to aggravate PD due to its effects on α-synuclein, mitochondrial dysfunction, and dopamine depletion. A few studies have even highlighted the higher vulnerability of PD patients to COVID-19. The sudden dramatic change in lifestyle caused by the pandemic and the widespread lockdowns that were implemented have added to the hidden sorrows of PD patients, as they already have a compromised mechanism for coping with stress. This review summarizes insights from basic science and the clinical effect of SARS-CoV-2 infection on the human brain, with a specific focus on PD.

Citations

Citations to this article as recorded by  
  • Assessment of the relationship between the dopaminergic pathway and severe acute respiratory syndrome coronavirus 2 infection, with related neuropathological features, and potential therapeutic approaches in COVID‐19 infection
    Yousef Rasmi, Ameneh Shokati, Shima Hatamkhani, Yeganeh Farnamian, Roya Naderi, Ladan Jalali
    Reviews in Medical Virology.2024;[Epub]     CrossRef
  • SARS-CoV-2 Infection to Premature Neuronal Aging and Neurodegenerative Diseases: Is there any Connection with Hypoxia?
    Narmadhaa Sivagurunathan, Latchoumycandane Calivarathan
    CNS & Neurological Disorders - Drug Targets.2024; 23(4): 431.     CrossRef
  • Deciphering the molecular pathways underlying dopaminergic neuronal damage in Parkinson's disease associated with SARS-CoV-2 infection
    Qiuhan Xu, Sisi Jiang, Ruiqing Kang, Yiling Wang, Baorong Zhang, Jun Tian
    Computers in Biology and Medicine.2024; 171: 108200.     CrossRef
  • Headache and Dizziness as Prevailing Clinical Manifestations in Parkinson's Patients Following COVID-19
    Mohammad Haddadi, Yasamin Meamarzadegan, Ali Vasheghani Farahani, Alireza Etrati Kooshali, Sheida Sarrafzadeh, Parsa Ghafari, Parsa Nobaveh, Omid Salahi Ardekani, Zahra Taghiabadi, Saeed Motlaghzadeh, Sepehr Damghani, Arash Letafati
    Archives of Neuroscience.2024;[Epub]     CrossRef
  • Axial Improvement after Casirivimab/Imdevimab Treatment for COVID-19 in Parkinson’s Disease
    Valentina Fioravanti, Francesco Cavallieri, Alessio Di Fonzo, Giulia Toschi, Sara Grisanti, Gaetano Salomone, Mario Zappia, Franco Valzania
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.2023; 50(5): 777.     CrossRef
  • Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms
    Pei Huang, Lin-Yuan Zhang, Yu-Yan Tan, Sheng-Di Chen
    Translational Neurodegeneration.2023;[Epub]     CrossRef
  • Does the SARS-CoV-2 Spike Receptor-Binding Domain Hamper the Amyloid Transformation of Alpha-Synuclein after All?
    Yulia Stroylova, Anastasiia Konstantinova, Victor Stroylov, Ivan Katrukha, Fedor Rozov, Vladimir Muronetz
    Biomedicines.2023; 11(2): 498.     CrossRef
  • Sex and age affect acute and persisting COVID-19 illness
    Anna Vasilevskaya, Asma Mushtaque, Michelle Y. Tsang, Batoul Alwazan, Margaret Herridge, Angela M. Cheung, Maria Carmela Tartaglia
    Scientific Reports.2023;[Epub]     CrossRef
  • Vulnerability of Parkinson’s Patients to COVID-19 and Its Consequences and Effects on Them: A Systematic Review
    Sorayya Rezayi, Meysam Rahmani Katigari, Leila Shahmoradi, Mehrbakhsh Nilashi, Hélio Teive
    Parkinson's Disease.2023; 2023: 1.     CrossRef
  • COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent
    Sebastián García Menéndez, Virna Margarita Martín Giménez, Michael F. Holick, Francisco J. Barrantes, Walter Manucha
    Life Sciences.2022; 297: 120464.     CrossRef
  • SARS-CoV-2 Proteins Interact with Alpha Synuclein and Induce Lewy Body-like Pathology In Vitro
    Zhengcun Wu, Xiuao Zhang, Zhangqiong Huang, Kaili Ma
    International Journal of Molecular Sciences.2022; 23(6): 3394.     CrossRef
  • COVID-19 and Parkinsonism: A Critical Appraisal
    Francesco Cavallieri, Valentina Fioravanti, Francesco Bove, Eleonora Del Prete, Sara Meoni, Sara Grisanti, Marialuisa Zedde, Rosario Pascarella, Elena Moro, Franco Valzania
    Biomolecules.2022; 12(7): 970.     CrossRef
  • SARS-CoV-2 mediated neurological disorders in COVID-19: Measuring the pathophysiology and immune response
    Pi-Ching Hsu, Md. Shahed-Al-Mahmud
    Life Sciences.2022; 308: 120981.     CrossRef
  • COVID-19 і хвороба Паркінсона
    I.M. Karaban, T.V. Hasiuk, N.V. Karasevych
    INTERNATIONAL NEUROLOGICAL JOURNAL.2022; 18(3): 46.     CrossRef
Management of Parkinson’s Disease in the COVID-19 Pandemic and Future Perspectives in the Era of Vaccination
Yue Hui Lau, Keng Ming Lau, Norlinah Mohamed Ibrahim
J Mov Disord. 2021;14(3):177-183.   Published online July 29, 2021
DOI: https://doi.org/10.14802/jmd.21034
  • 6,929 View
  • 156 Download
  • 11 Web of Science
  • 7 Crossref
AbstractAbstract PDF
The current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) has led to a serious global health crisis. Increasing evidence suggests that elderly individuals with underlying chronic diseases, including Parkinson’s disease (PD), are particularly vulnerable to this infection. Changes in the routine care of PD patients should be implemented carefully without affecting the quality provided. The utilization of telemedicine for clinical consultation, assessment and rehabilitation has also been widely recommended. Therefore, the aim of this review is to provide recommendations in the management of PD during the pandemic as well as in the early phase of vaccination programs to highlight the potential sequelae and future perspectives of vaccination and further research in PD. Even though a year has passed since COVID- 19 emerged, most of us are still facing great challenges in providing a continuum of care to patients with chronic neurological disorders. However, we should regard this health crisis as an opportunity to change our routine approach in managing PD patients and learn more about the impact of SARS-CoV-2. Hopefully, PD patients can be vaccinated promptly, and more detailed research related to PD in COVID-19 can still be carried out.

Citations

Citations to this article as recorded by  
  • Increasing exercise with a mobile app in people with Parkinson’s disease: a pilot study
    Jong Hyeon Ahn, Dongrul Shin, Dongyeong Lee, Hye Young Kim, Jinyoung Youn, Jin Whan Cho, Suzanne Kuys
    Brain Impairment.2024;[Epub]     CrossRef
  • Potential convergence of olfactory dysfunction in Parkinson’s disease and COVID-19: The role of neuroinflammation
    Hui Li, Junliang Qian, Youcui Wang, Juan Wang, Xiaoqing Mi, Le Qu, Ning Song, Junxia Xie
    Ageing Research Reviews.2024; 97: 102288.     CrossRef
  • A large survey on COVID-19 vaccination in patients with Parkinson’s disease and healthy population
    Chao Han, Zhen Zhen Zhao, Piu Chan, Fang Li, Chun Ling Chi, Xin Zhang, Yan Zhao, Jing Chen, Jing Hong Ma
    Vaccine.2023; 41(43): 6483.     CrossRef
  • Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review
    Jeremy M. Morowitz, Kaylyn B. Pogson, Daniel A. Roque, Frank C. Church
    Brain Sciences.2022; 12(5): 536.     CrossRef
  • Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson’s Disease Affected by COVID-19: A Narrative Review
    Jasjit S. Suri, Mahesh A. Maindarkar, Sudip Paul, Puneet Ahluwalia, Mrinalini Bhagawati, Luca Saba, Gavino Faa, Sanjay Saxena, Inder M. Singh, Paramjit S. Chadha, Monika Turk, Amer Johri, Narendra N. Khanna, Klaudija Viskovic, Sofia Mavrogeni, John R. Lai
    Diagnostics.2022; 12(7): 1543.     CrossRef
  • Movement disorders in COVID-19 times: impact on care in movement disorders and Parkinson disease
    Sabrina Poonja, K. Ray Chaudhuri, Janis M. Miyasaki
    Current Opinion in Neurology.2022; 35(4): 494.     CrossRef
  • Viruses, parkinsonism and Parkinson’s disease: the past, present and future
    Valentina Leta, Daniele Urso, Lucia Batzu, Yue Hui Lau, Donna Mathew, Iro Boura, Vanessa Raeder, Cristian Falup-Pecurariu, Daniel van Wamelen, K. Ray Chaudhuri
    Journal of Neural Transmission.2022; 129(9): 1119.     CrossRef
Letter to the editor
Resilience and Trauma among Patients with Parkinson’s Disease during the COVID-19 Pandemic
Roberto Erro, Sofia Cuoco, Emanuele Nigro, Raffaele Ragone, Paolo Barone
J Mov Disord. 2022;15(1):77-79.   Published online April 26, 2021
DOI: https://doi.org/10.14802/jmd.20126
  • 5,000 View
  • 168 Download
  • 2 Web of Science
  • 2 Crossref
PDFSupplementary Material

Citations

Citations to this article as recorded by  
  • Differential impact of resilience on demoralization and depression in Parkinson disease
    John M. de Figueiredo, Boheng Zhu, Amar S. Patel, Robert Kohn, Brian B. Koo, Elan D. Louis
    Frontiers in Psychiatry.2023;[Epub]     CrossRef
  • Reliability and validity of the novel Italian version of the 14-item Resilience Scale (RS-14) in adults
    Sofia Cuoco, Immacolata Carotenuto, Arianna Cappiello, Rossella Bisogno, Marina Picillo, Maria Teresa Pellecchia, Paolo Barone, Roberto Erro
    Neurological Sciences.2022; 43(5): 3079.     CrossRef
Case Report
Myoclonus-Ataxia Syndrome Associated with COVID-19
Kuldeep Shetty, Atul Manchakrao Jadhav, Ranjith Jayanthakumar, Seema Jamwal, Tejaswini Shanubhogue, Mallepalli Prabhakar Reddy, Gopal Krishna Dash, Radhika Manohar, Vivek Jacob Philip, Vikram Huded
J Mov Disord. 2021;14(2):153-156.   Published online April 6, 2021
DOI: https://doi.org/10.14802/jmd.20106
  • 8,080 View
  • 192 Download
  • 9 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary Material
Neurological manifestations of coronavirus disease (COVID-19) have increasingly been reported since the onset of the pandemic. Herein, we report a relatively new presentation. A patient in the convalescence period following a febrile illness with lower respiratory tract infection (fever, myalgia, nonproductive cough) presented with generalized disabling myoclonus, which is phenotypically suggestive of brainstem origin, along with additional truncal cerebellar ataxia. His neurology work-ups, such as brain MRI, electroencephalography, serum autoimmune and paraneoplastic antibody testing, were normal. His CT chest scan revealed right lower lung infiltrates, and serological and other laboratory testing did not show evidence of active infection. COVID-19 titers turned out to be strongly positive, suggestive of post-COVID-19 lung sequelae. He responded partially to antimyoclonic drugs and fully to a course of steroids, suggesting a para- or postinfectious immune-mediated pathophysiology. Myoclonusataxia syndrome appears to be a neurological manifestation of COVID-19 infection, and knowledge regarding this phenomenon should be increased among clinicians for better patient care in a pandemic situation.

Citations

Citations to this article as recorded by  
  • Opsoclonus Myoclonus Ataxia Syndrome Due to SARS-CoV-2
    Josef Finsterer, Fulvio A. Scorza
    Neuro-Ophthalmology.2023; 47(1): 1.     CrossRef
  • Myoclonus in patients with COVID‐19: Findings of autoantibodies against brain structures in cerebrospinal fluid
    Isa Lindqvist, Janet L. Cunningham, Jan Mulder, Amalia Feresiadou, Elham Rostami, Johan Virhammar, Eva Kumlien
    European Journal of Neurology.2023; 30(10): 3142.     CrossRef
  • Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19
    Kenta Osawa, Atsuhiko Sugiyama, Akiyuki Uzawa, Shigeki Hirano, Tatsuya Yamamoto, Masahiko Nezu, Nobuyuki Araki, Hiroki Kano, Satoshi Kuwabara
    Internal Medicine.2022; 61(7): 1071.     CrossRef
  • Post‐infectious cerebellar ataxia following COVID‐19 in a patient with epilepsy
    Sidhartha Chattopadhyay, Judhajit Sengupta, Sagar Basu
    Clinical and Experimental Neuroimmunology.2022; 13(4): 323.     CrossRef
  • Persistent neurological manifestations in long COVID-19 syndrome: A systematic review and meta-analysis
    Rizaldy Taslim Pinzon, Vincent Ongko Wijaya, Abraham Al Jody, Patrick Nalla Nunsio, Ranbebasa Bijak Buana
    Journal of Infection and Public Health.2022; 15(8): 856.     CrossRef
  • Anti-neuronal antibodies against brainstem antigens are associated with COVID-19
    Guglielmo Lucchese, Antje Vogelgesang, Fabian Boesl, Dina Raafat, Silva Holtfreter, Barbara M. Bröker, Angela Stufano, Robert Fleischmann, Harald Prüss, Christiana Franke, Agnes Flöel
    eBioMedicine.2022; 83: 104211.     CrossRef
  • Post–COVID‐19 Myoclonus–Ataxia Syndrome Responsive to Intravenous Immunoglobulins
    Massimiliano Godani, Alessandro Beronio, Giuseppe Lanza
    Movement Disorders Clinical Practice.2022;[Epub]     CrossRef
  • Spectrum of de novo movement disorders in the setting of COVID-19 infection: Part 2: Hyperkinetic movement disorders
    Mitesh Chandarana, Heli Shah, Soaham Desai
    Annals of Movement Disorders.2022; 5(1): 23.     CrossRef
  • Anti-GAD associated post-infectious cerebellitis after COVID-19 infection
    Ahmed Serkan Emekli, Asuman Parlak, Nejla Yılmaz Göcen, Murat Kürtüncü
    Neurological Sciences.2021; 42(10): 3995.     CrossRef
Original Article
Telemedicine in an Academic Movement Disorders Center during COVID-19
Christine Doss Esper, Laura Scorr, Sosi Papazian, Daniel Bartholomew, Gregory Jacob Esper, Stewart Alan Factor
J Mov Disord. 2021;14(2):119-125.   Published online March 18, 2021
DOI: https://doi.org/10.14802/jmd.20099
  • 6,770 View
  • 146 Download
  • 14 Web of Science
  • 15 Crossref
AbstractAbstract PDF
Objective
Telemedicine has rapidly gained momentum in movement disorder neurology during the coronavirus disease (COVID-19) pandemic to preserve clinical care while mitigating the risks of in-person visits. We present data from the rapid implementation of virtual visits in a large, academic, movement disorder practice during the COVID-19 pandemic.
Methods
We describe the strategic shift to virtual visits and retrospectively examine elements that impacted the ability to switch to telemedicine visits using historical prepandemic in-person data as a comparator, including demographics, distance driven, and diagnosis distribution, with an additional focus on patients with deep brain stimulators.
Results
A total of 686 telemedicine visits were performed over a five-week period (60% of those previously scheduled for in-office visits). The average age of participants was 65 years, 45% were female, and 73% were Caucasian. Men were more likely to make the transition (p = 0.02). Telemedicine patients lived farther from the clinic than those seen in person (66.47 km vs. 42.16 km, p < 0.001), age was not associated with making the switch, and patient satisfaction did not change. There was a significant shift in the distribution of movement disorder diagnoses seen by telemedicine compared to prepandemic in-person visits (p < 0.001). Patients with deep brain stimulators were more likely to use telemedicine (11.5% vs. 7%, p < 0.001).
Conclusion
Telemedicine is feasible, viable and relevant in the care of movement disorder patients, although health care disparities appear evident for women and minorities. Patients with deep brain stimulators preferred telemedicine in our study. Further study is warranted to explore these findings.

Citations

Citations to this article as recorded by  
  • Interest and Satisfaction of Telemedicine Use Among Ambulatory Neurology Patients in Western North Carolina During the COVID-19 Pandemic
    K. Alexander Soltany, Reyna Segovia Molina, Carly Pappo, Sharon Thomson, Kelly Pring, Siobhan Cox, Rebecca Merrill, Emily Fishman, Alexander Ambrosini, Gabby Bognet, Kristen Dodenhoff, Heidi Munger Clary, Lauren Strauss, Rachel Graham, Amy K. Guzik, Roy E
    Telemedicine and e-Health.2024; 30(4): e1071.     CrossRef
  • The Importance of Digital Health Literacy in an Evolving Parkinson’s Disease Care System
    Christine D. Esper, Blanca Y. Valdovinos, Ruth B. Schneider
    Journal of Parkinson's Disease.2024; : 1.     CrossRef
  • Neurological Examination via Telemedicine: An Updated Review Focusing on Movement Disorders
    Efthalia Angelopoulou, Christos Koros, Evangelia Stanitsa, Ioannis Stamelos, Dionysia Kontaxopoulou, Stella Fragkiadaki, John D. Papatriantafyllou, Evangelia Smaragdaki, Kalliopi Vourou, Dimosthenis Pavlou, Panagiotis D. Bamidis, Leonidas Stefanis, Sokrat
    Medicina.2024; 60(6): 958.     CrossRef
  • Long‐Lasting Impact of the COVID‐19 Pandemic on Patients with Parkinson's Disease and Their Relatives
    Andreas Wolfgang Wolff, Bernhard Haller, Antonia Franziska Demleitner, Dominik Pürner, Johanna Niederschweiberer, Isabell Cordts, Erica Westenberg, Paul Lingor
    Movement Disorders Clinical Practice.2023; 10(5): 819.     CrossRef
  • Telemedicine technologies and applications in the era of COVID-19 pandemic: A systematic review
    Esmaeil Mehraeen, SeyedAhmad SeyedAlinaghi, Mohammad Heydari, Amirali Karimi, Abdollah Mahdavi, Mehrnaz Mashoufi, Arezoo Sarmad, Peyman Mirghaderi, Ahmadreza Shamsabadi, Kowsar Qaderi, Pegah Mirzapour, Amirata Fakhfouri, Hadiseh Azadi Cheshmekabodi, Kimia
    Health Informatics Journal.2023; 29(2): 146045822311674.     CrossRef
  • Racial disparities in access to DBS: results of a real-world U.S. claims data analysis
    Michael Frassica, Drew S. Kern, Mitra Afshari, Allison T. Connolly, Chengyuan Wu, Nathan Rowland, Juan Ramirez-Castaneda, Mwiza Ushe, Claudia Salazar, Xenos Mason
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • Parkinson’s disease patients’ perspective on telephone visits during the COVID-19 pandemic
    Marta Magriço, Miguel Serôdio, Rita Ventura, Paulo Bugalho
    Journal of Neural Transmission.2023; 130(12): 1547.     CrossRef
  • Telemedicine in Neurology: A Scoping Review of Key Outcomes in Movement Disorders
    Emily Houston, Amanda G. Kennedy, Donna O'Malley, Terry Rabinowitz, Gail L. Rose, James Boyd
    Telemedicine and e-Health.2022; 28(3): 295.     CrossRef
  • Clinician and patient experience of neurology telephone consultations during the COVID-19 pandemic
    Tagore Nakornchai, Elena Conci, Anke Hensiek, J William L Brown
    Postgraduate Medical Journal.2022; 98(1161): 533.     CrossRef
  • Moving Forward from the COVID-19 Pandemic: Needed Changes in Movement Disorders Care and Research
    B. Y. Valdovinos, J. S. Modica, R. B. Schneider
    Current Neurology and Neuroscience Reports.2022; 22(2): 113.     CrossRef
  • Movement Disorder Specialists Survey Regarding Use of Telemedicine During the COVID-19 Pandemic
    Shadi Ghourchian, Yasar A. Torres-Yaghi, Stuart H. Isaacson, Fernando Pagan, Kelly E. Lyons, Brian James Nagle, Sanskruti Patel, Rajesh Pahwa
    Telemedicine and e-Health.2022; 28(11): 1651.     CrossRef
  • Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study
    Yaqian Xu, Megan P. Feeney, Matthew Surface, Dan Novak, Michelle S. Troche, James C. Beck, Roy N. Alcalay
    Movement Disorders.2022; 37(6): 1289.     CrossRef
  • Service process factors affecting patients’ and clinicians’ experiences on rapid teleconsultation implementation in out-patient neurology services during COVID-19 pandemic: a scoping review
    Guangxia Meng, Carrie McAiney, Christopher M. Perlman, Ian McKillop, Therese Tisseverasinghe, Helen H. Chen
    BMC Health Services Research.2022;[Epub]     CrossRef
  • Telemedicine in the Management of Parkinson’s Disease: Achievements, Challenges, and Future Perspectives
    Esther Cubo, Pedro David Delgado-López
    Brain Sciences.2022; 12(12): 1735.     CrossRef
  • Clinician Perceptions of the Negative Impact of Telehealth Services in the Management of Drug-Induced Movement Disorders and Opportunities for Quality Improvement: A 2021 Internet-Based Survey
    Rimal Bera, Morgan Bron, Betsy Benning, Samantha Cicero, Heintje Calara, Diane Darling, Ericha Franey, Kendra Martello, Charles Yonan
    Neuropsychiatric Disease and Treatment.2022; Volume 18: 2945.     CrossRef
Viewpoint
Impact and Challenges of the COVID-19 Pandemic on Patients Requiring Botulinum Toxin A Treatment
Azalea Tenerife Pajo, Adrian Isidoro Espiritu, Roland Dominic Go Jamora
J Mov Disord. 2021;14(1):29-33.   Published online January 12, 2021
DOI: https://doi.org/10.14802/jmd.20088
  • 8,518 View
  • 178 Download
  • 1 Web of Science
  • 1 Crossref
PDF

Citations

Citations to this article as recorded by  
  • COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study
    Yvonne Teuschl, Christian Bancher, Michael Brainin, Alexandra Dachenhausen, Karl Matz, Michaela M. Pinter
    Journal of Neural Transmission.2022; 129(1): 49.     CrossRef
Letter to the editor
Encephalopathy and Complex Hyperkinesia in a Patient with Severe Acute Respiratory Syndrome Coronavirus-2 Infection
Wenyang Li, Elif Pinar Coskun, Rolando Berger, John Thomas Slevin, Luther Creed Pettigrew
J Mov Disord. 2021;14(2):173-175.   Published online January 12, 2021
DOI: https://doi.org/10.14802/jmd.20084
  • 4,696 View
  • 58 Download
PDFSupplementary Material
Case Report
Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia
Emmaline Zantua Fernando, Jeryl Ritzi Tan Yu, Salvador Miclat Abad Santos, Roland Dominic Go Jamora
J Mov Disord. 2021;14(1):75-77.   Published online December 7, 2020
DOI: https://doi.org/10.14802/jmd.20091
  • 5,635 View
  • 122 Download
  • 4 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary Material
Hydroxychloroquine (HCQ) has been used as an investigational drug for patients with moderate to severe coronavirus disease 2019 (COVID-19). There have been concerns of potential harms from side effects of the drug. We present a case of a 38-year-old male who was started on HCQ for COVID-19 pneumonia. He was referred for evaluation of myoclonus of all extremities, which resolved after discontinuation of HCQ. The involuntary movements were first reported after the initiation of HCQ, persisted despite improvement in inflammatory and radiologic parameters and eventually resolved after HCQ discontinuation. This supports a possible causality related to adverse drug reactions from HCQ that have not been commonly reported.

Citations

Citations to this article as recorded by  
  • Safety profile of COVID-19 drugs in a real clinical setting
    Mei Nee Chiu, Maitry Bhardwaj, Sangeeta Pilkhwal Sah
    European Journal of Clinical Pharmacology.2022; 78(5): 733.     CrossRef
  • Eventos adversos no sistema nervoso central potencialmente relacionados aos medicamentos utilizados na COVID-19: revisão de escopo
    Vinícius de Mello, Vinícius de Paula Pereira, João Paulo Vilela Rodrigues, Suelem Tavares da Silva Penteado, Leonardo Régis Leira Pereira, Fabiana Rossi Varallo
    Revista Panamericana de Salud Pública.2022; 46: 1.     CrossRef
Brief communication
Deep Brain Stimulation Battery Exhaustion during the COVID-19 Pandemic: Crisis within a Crisis
Vikram Venkappayya Holla, Koti Neeraja, Bharath Kumar Surisetti, Shweta Prasad, Nitish Kamble, Dwarakanath Srinivas, Ravi Yadav, Pramod Kumar Pal
J Mov Disord. 2020;13(3):218-222.   Published online August 31, 2020
DOI: https://doi.org/10.14802/jmd.20073
  • 8,463 View
  • 117 Download
  • 16 Web of Science
  • 6 Crossref
AbstractAbstract PDF
Objective
The novel coronavirus disease (COVID-19) pandemic and public health measures to control it have resulted in unique challenges in the management of patients with deep brain stimulation (DBS). We report our experience with the management of acute worsening of symptoms due to battery exhaustion in 3 patients with DBS.
Methods
Patients with DBS for movement disorders who visited the emergency room due to battery exhaustion during the nationwide lockdown from April to May 2020 were included.
Results
Two patients with subthalamic nucleus-DBS for Parkinson’s disease (PD) and one with globus pallidus interna-DBS for generalized dystonia presented with acute worsening of symptoms due to battery exhaustion. Urgent battery replacement was performed in both patients with PD. The patient with generalized dystonia was managed with medication adjustment as he chose to defer battery replacement.
Conclusion
DBS battery replacement can be an emergency. Decisions regarding DBS battery replacement should be individualized during this COVID-19 pandemic.

Citations

Citations to this article as recorded by  
  • Lessons learned during COVID-19 pandemic, a worldwide survey: evolution of global neurosurgical practice
    Harsh DEORA, Amol RAHEJA, Shashwat MISHRA, Vivek TANDON, Edoardo AGOSTI, Pierlorenzo VEICESCHI, Kanwaljeet GARG, Vikas NAIK, Shweta KEDIA, Rajesh MEENA, Satya S. MUNJAL, Bipin CHAURASIA, Jack WELLINGTON, Davide LOCATELLI, Marco M. FONTANELLA, Manmohan SIN
    Journal of Neurosurgical Sciences.2024;[Epub]     CrossRef
  • Effects of COVID-19 on Synaptic and Neuronal Degeneration
    Mohammed S. Alqahtani, Mohamed Abbas, Mohammad Y. Alshahrani, Khulud Alabdullh, Amjad Alqarni, Fawaz F. Alqahtani, Layal K. Jambi, Adnan Alkhayat
    Brain Sciences.2023; 13(1): 131.     CrossRef
  • Needs and Perceptions of Patients With Dystonia During the COVID-19 Pandemic: A Qualitative Framework Analysis of Survey Responses From Italy
    Vittorio Rispoli, Matías Eduardo Díaz Crescitelli, Francesco Cavallieri, Francesca Antonelli, Stefano Meletti, Luca Ghirotto, Franco Valzania
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Parkinsonism hyperpyraexia syndrome in Parkinson's disease patients undergoing deep brain stimulation: An indirect consequence of COVID-19 lockdowns
    Onanong Phokaewvarangkul, Sasivimol Virameteekul, Roongroj Bhidayasiri
    Parkinsonism & Related Disorders.2021; 87: 39.     CrossRef
  • An Investigation Into Miniaturised Closed-Loop DBS Devices
    Dean M. Corva, Scott D. Adams, Kevin E. Bennet, Parastoo Hashemi, Michael Berk, Abbas Z. Kouzani
    IEEE Transactions on Medical Robotics and Bionics.2021; 3(3): 671.     CrossRef
  • Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey
    Carla Piano, Francesco Bove, Tommaso Tufo, Isabella Imbimbo, Danilo Genovese, Alessandro Stefani, Massimo Marano, Antonella Peppe, Livia Brusa, Rocco Cerroni, Francesco Motolese, Enrico Di Stasio, Marianna Mazza, Antonio Daniele, Alessandro Olivi, Paolo C
    Frontiers in Neurology.2020;[Epub]     CrossRef
Letter to the editor
COVID-19: Implications for Sudden Death in Parkinson’s Disease
Ana Claudia Fiorini, Marcelo Cunio Machado Fonseca, Carla Alessandra Scorza, Josef Finsterer, Antônio Márcio Rodrigues, Antônio-Carlos Guimarães de Almeida, Fulvio Alexandre Scorza
J Mov Disord. 2021;14(1):78-80.   Published online August 31, 2020
DOI: https://doi.org/10.14802/jmd.20065
  • 5,574 View
  • 136 Download
PDF

JMD : Journal of Movement Disorders Twitter